Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$24 Mln
P/E Ratio
--
P/B Ratio
2.6
Industry P/E
--
Debt to Equity
--
ROE
-31.59 %
ROCE
-528.83 %
Div. Yield
0 %
Book Value
674.74
EPS
-1782.62
CFO
$-71.96 Mln
EBITDA
$-92.69 Mln
Net Profit
$-101.74 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Annovis Bio Inc (ANVS)
| -76.25 | -30.15 | -76.16 | -88.15 | -55.09 | -20.24 | -- |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
|
|---|---|---|---|---|
|
Annovis Bio Inc (ANVS)
| -72.81 | 39.24 | -23.61 | 133.16 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.41 | 10,226.85 | 20.76 | 23.13 | |
| 297.96 | 9,219.66 | 24.15 | 58.42 | |
| 24.82 | 10,361.50 | -- | -28.77 | |
| 101.14 | 9,388.25 | 28.84 | 14.16 |
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3... to treat parkinson's disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial to treat later stages of alzheimer's disease and dementia. The company was incorporated in 2008 and is headquartered in Malvern, Pennsylvania. Address: 101 Lindenwood Drive, Malvern, PA, United States, 19355 Read more
Founder, CEO, President & Executive Director
Dr. Maria L. Maccecchini Ph.D.
Founder, CEO, President, Interim Principal Financial Officer & Executive Director
Dr. Maria L. Maccecchini Ph.D.
Headquarters
Malvern, PA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Annovis Bio Inc (ANVS) stood at $ 13,926 Mln as on 31-Dec-24
The share price of Annovis Bio Inc (ANVS) is $1.19 (NYSE) as of 17-Apr-2025 14:31 EDT. Annovis Bio Inc (ANVS) has given a return of -55.09% in the last 3 years.
Annovis Bio Inc (ANVS) has a market capitalisation of $ 24 Mln as on 16-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Annovis Bio Inc (ANVS) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Annovis Bio Inc (ANVS) and enter the required number of quantities and click on buy to purchase the shares of Annovis Bio Inc (ANVS).
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3 to treat parkinson's disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial to treat later stages of alzheimer's disease and dementia. The company was incorporated in 2008 and is headquartered in Malvern, Pennsylvania. Address: 101 Lindenwood Drive, Malvern, PA, United States, 19355
The CEO & director of Dr. Maria L. Maccecchini Ph.D.. is Annovis Bio Inc (ANVS), and CFO & Sr. VP is Dr. Maria L. Maccecchini Ph.D..
There is no promoter pledging in Annovis Bio Inc (ANVS).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,031
|
|
|
989
|
|
|
950
|
|
|
915
|
| Annovis Bio Inc (ANVS) | Ratios |
|---|---|
|
Return on equity(%)
|
-528.83
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Annovis Bio Inc (ANVS) was $0 Mln.
$-0.07
(
